Yale School of Medicine

Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor (2024) Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro AB, Rubenbauer L, Rao VS, Burlein S, et al. Journal article Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (2024) Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, et al. Journal article Multimodal assessment of brain stiffness variation in healthy subjects using magnetic resonance elastography and ultrasound time-harmonic elastography (2024) Klemmer Chandía S, Schattenfroh J, Brinker ST, Tzschaetzsch H, Sack I, Meyer T Journal article Multimodal assessment of brain stiffness variation in healthy subjects using magnetic resonance elastography and ultrasound time-harmonic elastography (2024) Klemmer Chandía S, Schattenfroh J, Brinker ST, Tzschaetzsch H, Sack I, Meyer T Journal article Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy (2024) Gudera JA, Baehring JM, Karschnia P Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article EANS Epilepsy surgery Brain Dissection Course Vienna 2024 (2024) Rössler K, Van Roost D, Schijns O, Ackermans L, Delev D, Batista PD, Erőss L, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article Exome sequencing identifies a likely causative variant in 53% of families with ciliopathy-related features on renal ultrasound after excluding NPHP1 deletions (2024) Deutsch K, Klämbt V, Kitzler TM, Jobst-Schwan T, Schneider R, Buerger F, Seltzsam S, et al. Journal article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article